The potential for tumor suppressor gene therapy in head and neck cancer

Andrew Birkeland, Megan L. Ludwig, Matthew E. Spector, J. Chad Brenner

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Head and neck squamous cell carcinoma remains a highly morbid and fatal disease. Importantly, genomic sequencing of head and neck cancers has identified frequent mutations in tumor suppressor genes. While targeted therapeutics increasingly are being investigated in head and neck cancer, the majority of these agents are against overactive/overexpressed oncogenes. Therapy to restore lost tumor suppressor gene function remains a key and under-addressed niche in trials for head and neck cancer. Recent advances in gene editing have captured the interest of both the scientific community and the public. As our technology for gene editing and gene expression modulation improves, addressing lost tumor suppressor gene function in head and neck cancers is becoming a reality. This review will summarize new techniques, challenges to implementation, future directions, and ethical ramifications of gene therapy in head and neck cancer.

Original languageEnglish (US)
JournalDiscovery Medicine
Volume21
Issue number113
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Tumor Suppressor Genes
Genetic Therapy
Oncogenes
Technology
Gene Expression
Mutation
Therapeutics
Gene Editing

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Birkeland, A., Ludwig, M. L., Spector, M. E., & Brenner, J. C. (2016). The potential for tumor suppressor gene therapy in head and neck cancer. Discovery Medicine, 21(113).

The potential for tumor suppressor gene therapy in head and neck cancer. / Birkeland, Andrew; Ludwig, Megan L.; Spector, Matthew E.; Brenner, J. Chad.

In: Discovery Medicine, Vol. 21, No. 113, 01.01.2016.

Research output: Contribution to journalArticle

Birkeland, A, Ludwig, ML, Spector, ME & Brenner, JC 2016, 'The potential for tumor suppressor gene therapy in head and neck cancer', Discovery Medicine, vol. 21, no. 113.
Birkeland, Andrew ; Ludwig, Megan L. ; Spector, Matthew E. ; Brenner, J. Chad. / The potential for tumor suppressor gene therapy in head and neck cancer. In: Discovery Medicine. 2016 ; Vol. 21, No. 113.
@article{11f20449ec17400297edced643f2ac87,
title = "The potential for tumor suppressor gene therapy in head and neck cancer",
abstract = "Head and neck squamous cell carcinoma remains a highly morbid and fatal disease. Importantly, genomic sequencing of head and neck cancers has identified frequent mutations in tumor suppressor genes. While targeted therapeutics increasingly are being investigated in head and neck cancer, the majority of these agents are against overactive/overexpressed oncogenes. Therapy to restore lost tumor suppressor gene function remains a key and under-addressed niche in trials for head and neck cancer. Recent advances in gene editing have captured the interest of both the scientific community and the public. As our technology for gene editing and gene expression modulation improves, addressing lost tumor suppressor gene function in head and neck cancers is becoming a reality. This review will summarize new techniques, challenges to implementation, future directions, and ethical ramifications of gene therapy in head and neck cancer.",
author = "Andrew Birkeland and Ludwig, {Megan L.} and Spector, {Matthew E.} and Brenner, {J. Chad}",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "21",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "113",

}

TY - JOUR

T1 - The potential for tumor suppressor gene therapy in head and neck cancer

AU - Birkeland, Andrew

AU - Ludwig, Megan L.

AU - Spector, Matthew E.

AU - Brenner, J. Chad

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Head and neck squamous cell carcinoma remains a highly morbid and fatal disease. Importantly, genomic sequencing of head and neck cancers has identified frequent mutations in tumor suppressor genes. While targeted therapeutics increasingly are being investigated in head and neck cancer, the majority of these agents are against overactive/overexpressed oncogenes. Therapy to restore lost tumor suppressor gene function remains a key and under-addressed niche in trials for head and neck cancer. Recent advances in gene editing have captured the interest of both the scientific community and the public. As our technology for gene editing and gene expression modulation improves, addressing lost tumor suppressor gene function in head and neck cancers is becoming a reality. This review will summarize new techniques, challenges to implementation, future directions, and ethical ramifications of gene therapy in head and neck cancer.

AB - Head and neck squamous cell carcinoma remains a highly morbid and fatal disease. Importantly, genomic sequencing of head and neck cancers has identified frequent mutations in tumor suppressor genes. While targeted therapeutics increasingly are being investigated in head and neck cancer, the majority of these agents are against overactive/overexpressed oncogenes. Therapy to restore lost tumor suppressor gene function remains a key and under-addressed niche in trials for head and neck cancer. Recent advances in gene editing have captured the interest of both the scientific community and the public. As our technology for gene editing and gene expression modulation improves, addressing lost tumor suppressor gene function in head and neck cancers is becoming a reality. This review will summarize new techniques, challenges to implementation, future directions, and ethical ramifications of gene therapy in head and neck cancer.

UR - http://www.scopus.com/inward/record.url?scp=84958725786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958725786&partnerID=8YFLogxK

M3 - Article

C2 - 26896601

AN - SCOPUS:84958725786

VL - 21

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 113

ER -